Search

Your search keyword '"Linhart, Aleš"' showing total 538 results

Search Constraints

Start Over You searched for: Author "Linhart, Aleš" Remove constraint Author: "Linhart, Aleš"
538 results on '"Linhart, Aleš"'

Search Results

1. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

2. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up

3. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

6. Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community

9. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

11. Metabolic Cardiomyopathy

12. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

13. Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy

16. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel

18. Pulmonary perfusion in long‐term survivors of COVID‐19‐related severe acute respiratory distress syndrome treated by extracorporeal membrane oxygenation.

20. Heart rate as an independent predictor of long term mortality of acute heart failure patients in sinus rhythm according to their ejection fraction: data from the AHEAD registry

21. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years

22. Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies

23. Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy

24. Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens

26. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

27. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

29. State‐of‐the‐art document on optimal contemporary management of cardiomyopathies

31. Longitudinal Trends in Severe Dyslipidemia in the Czech Population: The Czech MONICA and Czech Post-MONICA Study

33. Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11, 6189

38. Reply

41. State-of-the-art document on optimal contemporary management of cardiomyopathies

44. AHEAD score — Long-term risk classification in acute heart failure

45. Coronary CT angiography

48. (Multicentric Observational prospective cohort STudy of the Heart Failure outpatients management in the Czech Republic - MOST-HF. Rationale and Design)

Catalog

Books, media, physical & digital resources